This week’s IND update looks at FT536, a gene-edited natural killer cell therapy developed by Fate Therapeutics for the treatment of multiple solid...

Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics

Multiple new deals and developments and new base editor data from Intellia Therapeutics

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...